Cargando…
The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases
Misfolding and abnormal aggregation of proteins in the brain are implicated in the pathogenesis of various neurodegenerative diseases including Alzheimer's, Parkinson's, and the polyglutamine (polyQ) diseases. In the polyQ diseases, an abnormally expanded polyQ stretch triggers misfolding...
Autores principales: | Popiel, H. Akiko, Burke, James R., Strittmatter, Warren J., Oishi, Shinya, Fujii, Nobutaka, Takeuchi, Toshihide, Toda, Tatsushi, Wada, Keiji, Nagai, Yoshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268222/ https://www.ncbi.nlm.nih.gov/pubmed/22312459 http://dx.doi.org/10.4061/2011/265084 |
Ejemplares similares
-
Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism
por: Popiel, H. Akiko, et al.
Publicado: (2012) -
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
por: Takeuchi, Toshihide, et al.
Publicado: (2017) -
Molecular Origin of Polyglutamine Aggregation in Neurodegenerative Diseases
por: Khare, Sagar D, et al.
Publicado: (2005) -
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
por: Minakawa, Eiko N., et al.
Publicado: (2021) -
Na(+)/H(+) Exchangers Induce Autophagy in Neurons and Inhibit Polyglutamine-Induced Aggregate Formation
por: Togashi, Kazuya, et al.
Publicado: (2013)